share_log

Vivos Therapeutics | 8-K: Current report

Vivos Therapeutics | 8-K: Current report

Vivos Therapeutics | 8-K:重大事件
美股sec公告 ·  06/25 16:36
Moomoo AI 已提取核心訊息
Vivos Therapeutics, Inc., a Delaware-incorporated company listed on The Nasdaq Stock Market under the trading symbol VVOS, has filed a Current Report on Form 8-K with the SEC on June 25, 2024. The report addresses the company's non-compliance with Nasdaq's Listing Rule 5550(b)(1) regarding the minimum stockholders' equity of $2.5 million as of March 31, 2024. Following a $7.5 million private placement completed on June 10, 2024, Vivos Therapeutics believes it now meets the equity requirement. A hearing with a Nasdaq Hearings Panel is scheduled for June 27, 2024, where the company will present its case for continued listing on Nasdaq. The decision from the Panel is expected within 30 days of the hearing. The company acknowledges the risk of being unable to raise sufficient capital to maintain compliance with the Equity Requirement, which could lead to delisting from Nasdaq and have a material adverse effect on the company's operations and stock price.
Vivos Therapeutics, Inc., a Delaware-incorporated company listed on The Nasdaq Stock Market under the trading symbol VVOS, has filed a Current Report on Form 8-K with the SEC on June 25, 2024. The report addresses the company's non-compliance with Nasdaq's Listing Rule 5550(b)(1) regarding the minimum stockholders' equity of $2.5 million as of March 31, 2024. Following a $7.5 million private placement completed on June 10, 2024, Vivos Therapeutics believes it now meets the equity requirement. A hearing with a Nasdaq Hearings Panel is scheduled for June 27, 2024, where the company will present its case for continued listing on Nasdaq. The decision from the Panel is expected within 30 days of the hearing. The company acknowledges the risk of being unable to raise sufficient capital to maintain compliance with the Equity Requirement, which could lead to delisting from Nasdaq and have a material adverse effect on the company's operations and stock price.
納斯達克股票市場上掛牌的一家特拉華州註冊公司Vivos Therapeutics,交易標的爲VVOS,已於2024年6月25日向美國證券交易委員會提交了一個關於當前形勢的8-K表格。該報告針對公司在2024年3月31日財年末的股東權益最低額度方面未能符合納斯達克5550(b)(1)上市規則的情況。在2024年6月10日完成的750萬美元定向增發後,Vivos Therapeutics認爲它現在符合權益要求。納斯達克聽證委員會於2024年6月27日舉行,Vivos Therapeutics將在該聽證會上闡述其繼續在納斯達克上市的理由。委員會的決定預計在聽證會後的30天內公佈。公司意識到無法籌集足夠的資本以維持符合權益要求的風險,這可能導致從納斯達克除牌並對公司的運營和股價產生重大不利影響。
納斯達克股票市場上掛牌的一家特拉華州註冊公司Vivos Therapeutics,交易標的爲VVOS,已於2024年6月25日向美國證券交易委員會提交了一個關於當前形勢的8-K表格。該報告針對公司在2024年3月31日財年末的股東權益最低額度方面未能符合納斯達克5550(b)(1)上市規則的情況。在2024年6月10日完成的750萬美元定向增發後,Vivos Therapeutics認爲它現在符合權益要求。納斯達克聽證委員會於2024年6月27日舉行,Vivos Therapeutics將在該聽證會上闡述其繼續在納斯達克上市的理由。委員會的決定預計在聽證會後的30天內公佈。公司意識到無法籌集足夠的資本以維持符合權益要求的風險,這可能導致從納斯達克除牌並對公司的運營和股價產生重大不利影響。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息